Acromegaly Clinical Trial
— ACRO-POLISOfficial title:
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
NCT number | NCT02012127 |
Other study ID # | A-54-52030-266 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 2013 |
Est. completion date | June 2014 |
Verified date | August 2019 |
Source | Ipsen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to describe most characteristic association of signs and symptoms present at the time of acromegaly diagnosis.
Status | Completed |
Enrollment | 648 |
Est. completion date | June 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patient (greater than or equal to 18 years old) - Patient with acromegaly, diagnosed for less than 5 years Exclusion Criteria: - Patient who have objected to the collection of his/her data |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Sud | Amiens | |
France | CHU Besançon Hôpital Jean Minjoz | Besançon | |
France | Hôpital la Cavale Blanche | Brest | |
France | Chu Cote de Nacre | Caen | |
France | Hôpital Henri Mondor | Creteil | |
France | Chu de Grenoble Hôpital Albert Michallon | Grenoble | |
France | Hôpital Claude Huriez | Lille | |
France | Hôpital le Cluzeau | Limoges | |
France | Hôpital Neuro-cardiologique | Lyon | |
France | Hôpital de la Timone | Marseille | |
France | Hôpital Lepeyronie | Montpellier | |
France | Hôpitaux de Brabois | Nancy | |
France | CHR Orléans - Hôpital la Source | Orléans | |
France | CH de Bicetre | Paris | |
France | CH Pitie Salpetreire | Paris | |
France | Hôpital Lariboisiere | Paris | |
France | Hôpital Haut Leveque | Pessac | |
France | CHU Reims - Hôpital Robert Debre | Reims | |
France | Hôpital Sud Anne de Bretagne | Rennes | |
France | CHU Rouen - Hôpital de Bois Guillaume | Rouen | |
France | Hôptital Nord | Saint Etienne | |
France | Hôpital Civil | Strasbourg | |
France | Hôpital de Hautepierre | Strasbourg | |
France | Hôpital Larrey | Toulouse | |
France | CHU Bretonneau | Tours |
Lead Sponsor | Collaborator |
---|---|
Ipsen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of the most characteristic sign-and-symptom associations of acromegaly, collected by a patient questionnaire. | At the time of patient diagnosis, up to 3 months | ||
Secondary | Description of demographic and clinical characteristics of patients with acromegaly, collected by a patient questionnaire. | At the time of patient diagnosis, up to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06344650 -
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
|
||
Active, not recruiting |
NCT02092129 -
Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.
|
N/A | |
Active, not recruiting |
NCT01265121 -
Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
|
N/A | |
Terminated |
NCT00765323 -
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
|
Phase 3 | |
Completed |
NCT00531908 -
Physiopathology of Sodium Retention in Acromegaly
|
N/A | |
Completed |
NCT00500227 -
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
|
||
Completed |
NCT01278342 -
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
|
Phase 4 | |
Active, not recruiting |
NCT01809808 -
A Prospective Study of Outcome After Therapy for Acromegaly
|
||
Completed |
NCT00145405 -
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
|
Phase 4 | |
Completed |
NCT00210457 -
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
|
Phase 3 | |
Recruiting |
NCT05401084 -
Diet in the Management of Acromegaly
|
N/A | |
Recruiting |
NCT00005100 -
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
|
N/A | |
Completed |
NCT00521300 -
Preoperative Octreotide Treatment of Acromegaly
|
Phase 4 | |
Completed |
NCT03548415 -
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
|
Phase 2 | |
Not yet recruiting |
NCT04066569 -
Reproducibility and Utility of OGTT in Acromegaly
|
N/A | |
Not yet recruiting |
NCT05298891 -
Hypoproteic Diet in Acromegaly
|
N/A | |
Recruiting |
NCT04520646 -
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
Active, not recruiting |
NCT03252353 -
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
|
Phase 3 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|